GPCR
Price
$21.14
Change
-$0.32 (-1.49%)
Updated
Jun 6, 04:59 PM (EDT)
Capitalization
1.23B
62 days until earnings call
NERV
Price
$1.81
Change
+$0.02 (+1.12%)
Updated
Jun 6, 03:22 PM (EDT)
Capitalization
12.52M
67 days until earnings call
Interact to see
Advertisement

GPCR vs NERV

Header iconGPCR vs NERV Comparison
Open Charts GPCR vs NERVBanner chart's image
Structure Therapeutics
Price$21.14
Change-$0.32 (-1.49%)
Volume$11.78K
Capitalization1.23B
Minerva Neurosciences
Price$1.81
Change+$0.02 (+1.12%)
Volume$150
Capitalization12.52M
GPCR vs NERV Comparison Chart
Loading...
GPCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GPCR vs. NERV commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GPCR is a Hold and NERV is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (GPCR: $21.46 vs. NERV: $1.79)
Brand notoriety: GPCR and NERV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GPCR: 52% vs. NERV: 126%
Market capitalization -- GPCR: $1.23B vs. NERV: $12.52M
GPCR [@Biotechnology] is valued at $1.23B. NERV’s [@Biotechnology] market capitalization is $12.52M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GPCR’s FA Score shows that 1 FA rating(s) are green whileNERV’s FA Score has 0 green FA rating(s).

  • GPCR’s FA Score: 1 green, 4 red.
  • NERV’s FA Score: 0 green, 5 red.
According to our system of comparison, both GPCR and NERV are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GPCR’s TA Score shows that 3 TA indicator(s) are bullish.

  • GPCR’s TA Score: 3 bullish, 6 bearish.

Price Growth

GPCR (@Biotechnology) experienced а -4.28% price change this week, while NERV (@Biotechnology) price change was +19.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.92%. For the same industry, the average monthly price growth was +17.56%, and the average quarterly price growth was +3.51%.

Reported Earning Dates

GPCR is expected to report earnings on Aug 07, 2025.

NERV is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+11.92% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GPCR($1.24B) has a higher market cap than NERV($12.5M). NERV YTD gains are higher at: -19.427 vs. GPCR (-20.870). NERV has higher annual earnings (EBITDA): 6.02M vs. GPCR (-181.48M). GPCR has more cash in the bank: 837M vs. NERV (21.4M). NERV has less debt than GPCR: NERV (0) vs GPCR (7.59M). GPCR (0) and NERV (0) have equivalent revenues.
GPCRNERVGPCR / NERV
Capitalization1.24B12.5M9,880%
EBITDA-181.48M6.02M-3,013%
Gain YTD-20.870-19.427107%
P/E RatioN/A2.18-
Revenue00-
Total Cash837M21.4M3,911%
Total Debt7.59M0-
FUNDAMENTALS RATINGS
NERV: Fundamental Ratings
NERV
OUTLOOK RATING
1..100
20
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
58
P/E GROWTH RATING
1..100
99
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GPCR
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 3 days ago
87%
Declines
ODDS (%)
Bearish Trend 10 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
GPCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NTRS106.470.37
+0.35%
Northern Trust Corp
VNOM40.190.05
+0.12%
Viper Energy
UAN82.19-0.31
-0.38%
CVR Partners LP
DLHC5.13-0.12
-2.29%
DLH Holdings Corp
UBX0.69-0.03
-4.62%
Unity Biotechnology

NERV and

Correlation & Price change

A.I.dvisor indicates that over the last year, NERV has been loosely correlated with DNLI. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if NERV jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NERV
1D Price
Change %
NERV100%
-3.24%
DNLI - NERV
34%
Loosely correlated
-1.35%
GPCR - NERV
34%
Loosely correlated
-2.45%
CVAC - NERV
32%
Poorly correlated
+0.56%
ANAB - NERV
31%
Poorly correlated
-0.61%
ROIV - NERV
30%
Poorly correlated
-0.18%
More